Next Article in Journal
Contribution of Anoctamins to Cell Survival and Cell Death
Next Article in Special Issue
Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
Previous Article in Journal
Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets
Previous Article in Special Issue
CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer
Open AccessReview

Angiogenesis in Pancreatic Cancer: Pre-Clinical and Clinical Studies

Department of Basic Medical Sciences, Neurosciences and Sensory Organs, Section of Human Anatomy and Histology, University of Bari Medical School Bari, 70124 Bari, Italy
Author to whom correspondence should be addressed.
Cancers 2019, 11(3), 381;
Received: 11 February 2019 / Revised: 11 March 2019 / Accepted: 14 March 2019 / Published: 18 March 2019
(This article belongs to the Special Issue Advances in Pancreatic Cancer Research)
Angiogenesis is a crucial event in tumor development and progression, occurring by different mechanisms and it is driven by pro- and anti-angiogenic molecules. Pancreatic cancer vascularization is characterized by a high microvascular density, impaired microvessel integrity and poor perfused vessels with heterogeneous distribution. In this review article, after a brief introduction on pancreatic cancer classification and on angiogenesis mechanisms involved in its progression, the pre-clinical and clinical trials conducted in pancreatic cancer treatment using anti-angiogenic inhibitors will be described. Finally, we will discuss the anti-angiogenic therapy paradox between the advantage to abolish vessel supply to block tumor growth and the disadvantage due to reduction of drug delivery at the same time. The purpose is to identify new anti-angiogenic molecules that may enhance treatment regimen. View Full-Text
Keywords: angiogenesis; anti-angiogenic therapy; pancreatic cancer; tumor progression angiogenesis; anti-angiogenic therapy; pancreatic cancer; tumor progression
Show Figures

Figure 1

MDPI and ACS Style

Annese, T.; Tamma, R.; Ruggieri, S.; Ribatti, D. Angiogenesis in Pancreatic Cancer: Pre-Clinical and Clinical Studies. Cancers 2019, 11, 381.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop